Departments of *Radiation Oncology †Medical Oncology ‡Otolaryngology, Beth Israel Medical Center, New York, NY.
Am J Clin Oncol. 2014 Feb;37(1):57-62. doi: 10.1097/COC.0b013e31826b9920.
To retrospectively review our single institution experience of patients with tonsillar squamous cell carcinoma.
Between 1999 and 2005, a total of 79 patients were identified. Stage distribution was as follows: stages I-II, III, IVA, and IVB were in 6, 14, 43, and 16 patients, respectively. Sixty-three patients (80%) were male. Median age was 55.5 years. Treatment generally consisted of external beam radiation therapy (RT) (median dose, 70 Gy), concomitant chemotherapy (CCRT) (cisplatin 100 mg/m on days 1, 22, and 43), and neck dissection (ND), and was administered as follows: stages I/II, 6 patients received RT alone; stages III/IVA, 20, 5, and 32 patients received RT alone, CCRT, and CCRT followed by ND, respectively; stage IVB, 9 and 7 patients received CCRT and CCRT plus ND, respectively.
After a median follow-up of 56 months (range, 12 to 122 mo), the 5-year local control (LC), regional control (RC), distant control (DC), and overall survival (OS) by stage were as follows: stage I-II 100%, 100%, 100%, 100%; stage III-IVA 98%, 96%, 95%, and 88%; stage IVB 100%, 100%, 69%, and 66%, respectively. Among stage IVB patients, DC was significantly lower (P=0.01) and a trend toward lower OS was noted (P=0.08). Long-term percutaneous endoscopic gastrostomy dependence was noted in 3% of them who had received CCRT. The effect of both chemotherapy and ND on treatment outcomes was analyzed; in stage III/IVA patients treated with or without chemotherapy, LC was 97% and 100% (P=0.43); RC was 92% and 100%(P=0.27); and DC was 91% and 94% (P=0.92), respectively. In stage III/IVA, patients treated with CCRT with or without ND, RC was 100% and 88%, respectively (P=0.087).
Primary radiotherapy with or without CCRT followed by ND provides excellent tumor control with acceptable toxicity in treating squamous cell carcinoma of the tonsil.
回顾分析我院扁桃体鳞状细胞癌患者的治疗经验。
1999 年至 2005 年间,共纳入 79 例患者。分期为:Ⅰ-Ⅱ期、Ⅲ期、ⅣA 期和ⅣB 期分别为 6、14、43 和 16 例。63 例(80%)为男性,中位年龄 55.5 岁。治疗方案为单纯外照射放疗(中位剂量 70Gy)、同期放化疗(顺铂 100mg/m2,第 1、22、43 天给药)加颈清扫术(ND),具体如下:Ⅰ/Ⅱ期 6 例患者仅接受放疗,Ⅲ/ⅣA 期 20、5、32 例患者分别仅接受放疗、同期放化疗和同期放化疗加 ND,ⅣB 期 9、7 例患者分别接受同期放化疗和同期放化疗加 ND。
中位随访 56 个月(12-122 个月)后,各期的 5 年局部控制率(LC)、区域控制率(RC)、无远处转移生存率(DC)和总生存率(OS)分别为:Ⅰ-Ⅱ期 100%、100%、100%、100%;Ⅲ/ⅣA 期 98%、96%、95%、88%;ⅣB 期 100%、100%、69%、66%。ⅣB 期患者 DC 明显较低(P=0.01),OS 也有降低趋势(P=0.08)。3%接受同期放化疗的患者长期依赖经皮内镜下胃造瘘术。分析化疗和 ND 对治疗结果的影响,Ⅲ/ⅣA 期接受或未接受化疗的患者,LC 分别为 97%和 100%(P=0.43),RC 分别为 92%和 100%(P=0.27),DC 分别为 91%和 94%(P=0.92);Ⅲ/ⅣA 期接受同期放化疗加 ND 或单纯 ND 的患者,RC 分别为 100%和 88%(P=0.087)。
单纯放疗或同期放化疗加 ND 治疗扁桃体鳞状细胞癌可获得极好的肿瘤控制效果,毒性可接受。